[
    [
        {
            "time": "",
            "original_text": "【康泰生物】19Q3季报点评：Q3四联苗批签发恢复良好，销售费用率显著降低",
            "features": {
                "keywords": [
                    "康泰生物",
                    "19Q3季报",
                    "四联苗",
                    "批签发",
                    "恢复良好",
                    "销售费用率",
                    "显著降低"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【康泰生物】19Q3季报点评：Q3四联苗批签发恢复良好，销售费用率显著降低",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]